{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T23:44:39Z","timestamp":1769557479398,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T00:00:00Z","timestamp":1654300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T00:00:00Z","timestamp":1654300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s00432-022-04079-x","type":"journal-article","created":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T10:02:31Z","timestamp":1654336951000},"page":"2375-2386","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Liposomal formulations for lung cancer treatment in the last two decades: a systematic review"],"prefix":"10.1007","volume":"148","author":[{"given":"Filipa","family":"Can\u00e3o","sequence":"first","affiliation":[]},{"given":"Helena","family":"Ferreira","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3041-0687","authenticated-orcid":false,"given":"Nuno M.","family":"Neves","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,6,4]]},"reference":[{"key":"4079_CR1","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1517\/13543780903114168","volume":"18","author":"T Boulikas","year":"2009","unstructured":"Boulikas T (2009) Clinical overview on lipoplatin: a successful liposomal formulation of cisplatin. Expert Opin Investig Drugs 18:1197\u20131218","journal-title":"Expert Opin Investig Drugs"},{"key":"4079_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/pharmaceutics9020012","volume":"9","author":"U Bulbake","year":"2017","unstructured":"Bulbake U, Doppalapudi S, Kommineni N, Khan W (2017) Liposomal formulations in clinical use: an updated review. Pharmaceutics 9:12","journal-title":"Pharmaceutics"},{"key":"4079_CR3","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s00432-011-1003-3","volume":"137","author":"C Butts","year":"2011","unstructured":"Butts C, Maksymiuk A, Goss G, Souli\u00e8res D, Marshall E et al (2011) Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J Cancer Res Clin Oncol 137:1337\u20131342","journal-title":"J Cancer Res Clin Oncol"},{"key":"4079_CR4","doi-asserted-by":"publisher","first-page":"6674","DOI":"10.1200\/JCO.2005.13.011","volume":"23","author":"C Butts","year":"2005","unstructured":"Butts C, Murray N, Maksymiuk A, Goss G, Marshall E et al (2005) Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 23:6674\u20136681","journal-title":"J Clin Oncol"},{"key":"4079_CR5","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3816\/CLC.2010.n.101","volume":"11","author":"C Butts","year":"2010","unstructured":"Butts C, Murray RN, Smith CJ, Ellis PM, Jasas K et al (2010) A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer. Clin Lung Cancer 11:391\u2013395","journal-title":"Clin Lung Cancer"},{"key":"4079_CR6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S1470-2045(13)70510-2","volume":"15","author":"C Butts","year":"2014","unstructured":"Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L et al (2014) Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 15:59\u201368","journal-title":"Lancet Oncol"},{"key":"4079_CR7","unstructured":"CASP (2018) Critical appraisal skills programme: randomised controlled trial 2018"},{"key":"4079_CR8","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00280-018-3640-6","volume":"82","author":"G Chen","year":"2018","unstructured":"Chen G, Sheng L, Du X (2018) Efficacy and safety of liposome-paclitaxel and carboplatin based concurrent chemoradiotherapy for locally advanced lung squamous cell carcinoma. Cancer Chemother Pharmacol 82:505\u2013510","journal-title":"Cancer Chemother Pharmacol"},{"key":"4079_CR9","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.nano.2016.07.012","volume":"13","author":"L Giodini","year":"2017","unstructured":"Giodini L, Re FL, Campagnol D, Marangon E, Posocco B et al (2017) Nanocarriers in cancer clinical practice: a pharmacokinetic issue. Nanomedicine 13:583\u2013599","journal-title":"Nanomedicine"},{"key":"4079_CR10","unstructured":"Institute NC (2020) Common terminology criteria for adverse events v6.0 (CTCAE)"},{"key":"4079_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.lungcan.2017.01.007","volume":"105","author":"N Katakami","year":"2017","unstructured":"Katakami N, Hida T, Nokihara H, Imamura F, Sakai H et al (2017) Phase I\/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer. Lung Cancer 105:23\u201330","journal-title":"Lung Cancer"},{"key":"4079_CR12","first-page":"Cd006910","volume":"2013","author":"TA Lawrie","year":"2013","unstructured":"Lawrie TA, Bryant A, Cameron A, Gray E, Morrison J (2013) Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. Cochrane Database Syst Rev 2013:Cd006910","journal-title":"Cochrane Database Syst Rev"},{"key":"4079_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3816\/CLC.2003.n.024","volume":"5","author":"NB Leighl","year":"2003","unstructured":"Leighl NB, Burkes RL, Dancey JE, Lopez PG, Higgins BP et al (2003) A phase I study of pegylated liposomal doxorubicin hydrochloride (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small-cell lung cancer. Clin Lung Cancer 5:107\u2013112","journal-title":"Clin Lung Cancer"},{"key":"4079_CR14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.lungcan.2006.02.006","volume":"52","author":"NB Leighl","year":"2006","unstructured":"Leighl NB, Goss GD, Lopez PG, Burkes RL, Dancey JE et al (2006) Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer. Lung Cancer 52:327\u2013332","journal-title":"Lung Cancer"},{"key":"4079_CR15","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s12032-014-0345-5","volume":"32","author":"B Lu","year":"2015","unstructured":"Lu B, Sun L, Yan X, Ai Z, Xu J (2015) Intratumoral chemotherapy with paclitaxel liposome combined with systemic chemotherapy: a new method of neoadjuvant chemotherapy for stage III unresectable non-small cell lung cancer. Med Oncol 32:345","journal-title":"Med Oncol"},{"key":"4079_CR16","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.tranon.2019.01.008","volume":"12","author":"WZ Lv","year":"2019","unstructured":"Lv WZ, Lin Z, Wang SY, Lv BJ, Wang ZH et al (2019) Phase II study of a Bi-weekly chemotherapy regimen of combined liposomal paclitaxel and nedaplatin for the treatment of advanced squamous cell lung cancer. Transl Oncol 12:656\u2013660","journal-title":"Transl Oncol"},{"key":"4079_CR17","doi-asserted-by":"publisher","first-page":"13249","DOI":"10.1038\/s41598-017-13320-4","volume":"7","author":"JU Menon","year":"2017","unstructured":"Menon JU, Kuriakose A, Iyer R, Hernandez E, Gandee L et al (2017) Dual-drug containing core-shell nanoparticles for lung cancer therapy. Sci Rep 7:13249","journal-title":"Sci Rep"},{"key":"4079_CR18","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1093\/annonc\/mdv104","volume":"26","author":"P Mitchell","year":"2015","unstructured":"Mitchell P, Thatcher N, Socinski MA, Wasilewska-Tesluk E, Horwood K et al (2015) Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses. Ann Oncol 26:1134\u20131142","journal-title":"Ann Oncol"},{"key":"4079_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535","journal-title":"BMJ"},{"key":"4079_CR20","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.lungcan.2009.06.017","volume":"68","author":"N Mylonakis","year":"2010","unstructured":"Mylonakis N, Athanasiou A, Ziras N, Angel J, Rapti A et al (2010) Phase II study of liposomal cisplatin (Lipoplatin) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB\/IV) non-small cell lung cancer. Lung Cancer 68:240\u2013247","journal-title":"Lung Cancer"},{"key":"4079_CR21","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/annonc\/mdw326","volume":"27","author":"S Novello","year":"2016","unstructured":"Novello S, Barlesi F, Califano R, Cufer T, Ekman S et al (2016) Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol 27:v1\u2013v27","journal-title":"Ann Oncol"},{"key":"4079_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0169-5002(01)00269-0","volume":"35","author":"G Numico","year":"2002","unstructured":"Numico G, Castiglione F, Granetto C, Garrone O, Mariani G et al (2002) Single-agent pegylated liposomal doxorubicin (Caelix) in chemotherapy pretreated non-small cell lung cancer patients: a pilot trial. Lung Cancer 35:59\u201364","journal-title":"Lung Cancer"},{"key":"4079_CR23","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3816\/CLC.2001.n.018","volume":"3","author":"M Palmer","year":"2001","unstructured":"Palmer M, Parker J, Modi S, Butts C, Smylie M et al (2001) Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB\/IV non-small-cell lung cancer. Clin Lung Cancer 3:49\u201357 (Discussion 58)","journal-title":"Clin Lung Cancer"},{"key":"4079_CR24","first-page":"1427","volume":"25","author":"G Patlakas","year":"2005","unstructured":"Patlakas G, Bouros D, Tsantekidou-Pozova S, Koukourakis MI (2005) Triplet chemotherapy with docetaxel, gemcitabine and liposomal doxorubicin, supported with subcutaneous amifostine and hemopoietic growth factors, in advanced non-small cell lung cancer. Anticancer Res 25:1427\u20131431","journal-title":"Anticancer Res"},{"key":"4079_CR25","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1179\/joc.2009.21.1.86","volume":"21","author":"A Ravaioli","year":"2009","unstructured":"Ravaioli A, Papi M, Pasquini E, Marangolo M, Rudnas B et al (2009) Lipoplatin monotherapy: a phase II trial of second-line treatment of metastatic non-small-cell lung cancer. J Chemother 21:86\u201390","journal-title":"J Chemother"},{"key":"4079_CR26","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1208\/s12248-017-0152-y","volume":"19","author":"B Sharma","year":"2017","unstructured":"Sharma B, Crist RM, Adiseshaiah PP (2017) Nanotechnology as a delivery tool for precision cancer therapies. AAPS J 19:1632\u20131642","journal-title":"AAPS J"},{"key":"4079_CR27","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y et al (2003) Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 73:712\u2013716","journal-title":"ANZ J Surg"},{"key":"4079_CR28","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1093\/annonc\/mdq234","volume":"21","author":"GP Stathopoulos","year":"2010","unstructured":"Stathopoulos GP, Antoniou D, Dimitroulis J, Michalopoulou P, Bastas A et al (2010) Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial. Ann Oncol 21:2227\u20132232","journal-title":"Ann Oncol"},{"key":"4079_CR29","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s00280-011-1572-5","volume":"68","author":"GP Stathopoulos","year":"2011","unstructured":"Stathopoulos GP, Antoniou D, Dimitroulis J, Stathopoulos J, Marosis K et al (2011) Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer. Cancer Chemother Pharmacol 68:945\u2013950","journal-title":"Cancer Chemother Pharmacol"},{"key":"4079_CR30","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249","journal-title":"CA Cancer J Clin"},{"key":"4079_CR31","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1158\/1078-0432.CCR-12-2935","volume":"19","author":"LC Villaruz","year":"2013","unstructured":"Villaruz LC, Socinski MA (2013) The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurement. Clin Cancer Res 19:2629\u20132636","journal-title":"Clin Cancer Res"},{"key":"4079_CR32","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3816\/CLC.2000.n.025","volume":"2","author":"EE Vokes","year":"2000","unstructured":"Vokes EE, Gordon GS, Mauer AM, Rudin CM, Krauss SA et al (2000) A phase I study of STEALTH cisplatin (SPI-77) and vinorelbine in patients with advanced non small-cell lung cancer. Clin Lung Cancer 2:128\u2013132","journal-title":"Clin Lung Cancer"},{"key":"4079_CR33","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/j.ejca.2010.02.002","volume":"46","author":"X Wang","year":"2010","unstructured":"Wang X, Zhou J, Wang Y, Zhu Z, Lu Y et al (2010) A phase I clinical and pharmacokinetic study of paclitaxel liposome infused in non-small cell lung cancer patients with malignant pleural effusions. Eur J Cancer 46:1474\u20131480","journal-title":"Eur J Cancer"},{"key":"4079_CR34","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1200\/JCO.1990.8.7.1263","volume":"8","author":"RB Weiss","year":"1990","unstructured":"Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ et al (1990) Hypersensitivity reactions from taxol. J Clin Oncol 8:1263\u20131268","journal-title":"J Clin Oncol"},{"key":"4079_CR35","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/sj.bjc.6603345","volume":"95","author":"SC White","year":"2006","unstructured":"White SC, Lorigan P, Margison GP, Margison JM, Martin F et al (2006) Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br J Cancer 95:822\u2013828","journal-title":"Br J Cancer"},{"key":"4079_CR36","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.semcancer.2020.02.009","volume":"69","author":"C Woodman","year":"2021","unstructured":"Woodman C, Vundu G, George A, Wilson CM (2021) Applications and strategies in nanodiagnosis and nanotherapy in lung cancer. Semin Cancer Biol 69:349\u2013364","journal-title":"Semin Cancer Biol"},{"key":"4079_CR37","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.4161\/hv.29836","volume":"10","author":"GT Wurz","year":"2014","unstructured":"Wurz GT, Kao C-J, Wolf M, DeGregorio MW (2014) Tecemotide: an antigen-specific cancer immunotherapy. Hum Vaccin Immunother 10:3383\u20133393","journal-title":"Hum Vaccin Immunother"},{"key":"4079_CR38","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00280-010-1427-5","volume":"68","author":"N Xenidis","year":"2011","unstructured":"Xenidis N, Vardakis N, Varthalitis I, Giassas S, Kontopodis E et al (2011) \u0391 multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer. Cancer Chemother Pharmacol 68:63\u201368","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04079-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04079-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04079-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T03:30:33Z","timestamp":1659583833000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04079-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,4]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["4079"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04079-x","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,4]]},"assertion":[{"value":"2 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}